Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    Animal Pharm   
Email ID
Password
Forgotten password?
Sign me in automatically next time
Home
Product Sector
Regulatory Region
Pre-marketing Regulation
Post-marketing Regulation
Healthcare Systems
Legal
MedTech
|
Pharmaceuticals
|
Biologics
|
Advanced Therapies
|
Combination Products
|
Veterinary
|
Diagnostics
|
Scrip Regulatory Affairs
EU agency's CHMP meeting on controversial rosiglitazone-containing drugs nears
07 September 2010
Neena Brizmohun

The European Medicines Agency's human drugs evaluation committee, the CHMP, is to meet on 8 September to discuss the ongoing benefit:risk review of Avandia and two other diabetes medicines containing rosiglitazone, which has been linked with a raised risk of cardiovascular events1...

Please login to read the full article.
 
Not a subscriber ?  
 
 
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
   
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Product Sector
Regulatory Region
Pre-marketing Regulation
Post-marketing Regulation
Healthcare Systems
Legal
Terms &Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Clinica
Scrip
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm